Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Vardhman Life Sciences Pvt Ltd

    Vardhman Life Sciences Pvt Ltd has been promoted by Vardhman Chemtech Ltd and Mr Sushil Kumar Singla who hold 51% and 49% stake respectively. VLSPL was originally incorporated

  • No Image
    Vasista Life Sciences Pvt Ltd

    Vasista Life sciences Pvt. Ltd. was established in 2010 for producing manufacture, sourcing and supply of bulk drugs, Drug intermediates and Fine chemicals.

  • No Image
    VAV Life Sciences Pvt Ltd

    VAV Life Sciences Pvt Ltd (VAV) commenced its operations in the year 2003. It is an integrated life science company provides solutions in the field of active pharmaceutical ingr

  • No Image
    Venkat Pharma Ltd

    VPL(An ISO 9002 Company) has the potential to manufacture a large variety of Pharmaceutical formulations, Herbal Extracts and formulations, generics at short notice followed by